CareCost Prior authorization
Required
Check what the payer requires before you administer Lucentis.
Prior authorization · clinical prerequisites · quantity limits · reauthorization
27 payer policy sets carry a ranibizumab coverage policy · source-linked · reviewed August 2026
Aetna + wet AMD is shown as a live example until you choose a payer.
This payer requires an approval on file before Lucentis is purchased or administered for this member.
Precertification of aflibercept [(Eylea), (Eylea HD)], aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili), aflibercept-mrbb (Ahzantive), aflibercept-yszy (Opuviz), brolucizumab-dbll (Beovu), faricimab-svoa (Vabysmo), ranibizumab (Lucentis)
Covered under ICD-10 H35.32.
medically necessary for the treatment of the following indications: Diabetic macular edema; Diabetic retinopathy; Macular edema following retinal vein occlusion; Myopic choroidal neovascularization; Neovascular (wet) age-related macular degeneration
The policy names the dose and frequency it pays for.
Lucentis 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month
What opens in CareCost
Aetna · Lucentis · Wet AMD
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Lucentis · Wet AMD
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Lucentis coverage requirements across 27 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · Regence · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →21 of 27 commercial payers with a ranibizumab policy require prior authorization. Clinical prerequisite, quantity-limit and reauthorization rules vary by indication and by plan; 396 rules apply across the 27 payers CareCost has read.
21 require PA · 19 require another product first · 6 restrict site of care · 35 rules set quantity limits
21 of the 27 ranibizumab policies CareCost has read require an approval on file before Lucentis is purchased or administered.
Coverage depends on the indication in the payer’s ranibizumab policy and the ICD-10 code billed: wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy or myopic choroidal neovascularization.
19 of 27 payers require another product first. Bevacizumab (Avastin) is named most often, at Florida Blue, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, Capital BlueCross, Centene, Cigna, Excellus and Highmark. Several other payers run a preferred-product tier naming Lucentis, Byooviz or Cimerli instead — BCBS Arkansas’s preferred list runs to Byooviz, Lucentis, Pavblu and Vabysmo.
35 rules set a per-eye monthly ceiling at the labeled dose: 10 billable units every 28 days for wet AMD, RVO and myopic CNV, or 6 billable units every 28 days for DME and DR, with myopic CNV additionally capped at up to 3 months. Most payer policies write that ceiling directly into the coverage criteria.
5 rules set a renewal window, most commonly every 12 months, before a payer approves continued treatment.
6 payers CareCost has read restrict where the injection can be administered.
Nine products share the anti-VEGF injection class that treats wet AMD, macular edema after retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization: Lucentis itself (J2778, Genentech), its biosimilars Byooviz (Q5124, Biogen / Samsung Bioepis) and Cimerli (Q5128, Sandoz, US commercialization paused in 2025), and the alternatives Eylea (J0178, Regeneron), Eylea HD (J0177, Regeneron), Pavblu (Q5147, Amgen), Vabysmo (J2777, Genentech), Beovu (J0179, Novartis) and repackaged bevacizumab, Avastin (J9035, off-label). 19 of the 27 ranibizumab policies CareCost has read require another product first, and which product depends on the payer.
| Payer | Indication | Rule, quoted from the policy |
|---|---|---|
| BCBS Arkansas Commercial |
All ranibizumab indications | “Select products (e.g., Byooviz, Lucentis, Pavblu, Vabysmo) are preferred where there is an FDA approved indication for the biosimilar product and for all off-label uses of the reference product.” |
| BCBS South Carolina Commercial |
All ranibizumab indications | Lists Byooviz, Cimerli and Lucentis as preferred; for non-preferred products it requires “a trial and failure of TWO preferred therapy.” |
| UnitedHealthcare Commercial |
All ranibizumab indications | “Avastin, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, and Vabysmo are the preferred ophthalmologic VEGF or dual VEGF/Ang-2 inhibitor products” — “Beovu® and Byooviz™ are typically excluded from coverage.” |
| Independence Blue Cross Commercial |
All ranibizumab indications | “The Company has designated bevacizumab (all brands) as its LEVEL 1 PREFERRED PRODUCTS, followed by ranibizumab (Lucentis, Byooviz, Cimerli), as its LEVEL 2 PREFERRED PRODUCTS.” |
| Anthem / Elevance Commercial |
All ranibizumab indications | CC-0072 VEGF Inhibitors Step Therapy, effective 10/30/2023, lists Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis and Vabysmo as preferred agents. |
There is no national coverage determination for ranibizumab. Coverage runs through your MAC’s LCD for intravitreal anti-VEGF drugs; the governing local coverage determinations are published in the CMS Medicare Coverage Database, and a MAC can differ from its neighbour on the same drug.
This is the Original Medicare answer. A Medicare Advantage plan administers the same Part B benefit but can layer its own prior-authorization rules on top — check the plan’s own policy rather than assuming the Original Medicare rules below carry over.
The diagnosis selector above keys on the same indication codes shown in the table: the Clearance corpus stores each payer’s rules against the indication, not the ICD-10 code by itself, so picking “Wet AMD” or “Diabetic macular edema” is what routes the scan to the right rules. Each ICD-10 code also carries its own laterality (a right-eye, left-eye or bilateral 7th character), which belongs on the claim line alongside the RT, LT or 50 modifier. Pick the payer and the indication, and the scan reads back that payer’s prior-authorization, clinical-prerequisite, quantity-limit and reauthorization rules for it.
MUE J2778 is 10 units per day (two eyes at 5 units each). Lucentis is not reported with an administration code: the injection itself is the procedure, 67028, reported per eye, RT or LT on the line, or once with modifier 50 when both eyes are injected at the same visit, allowed at 150% of the fee schedule. The drug line carries the same eye modifier beside JZ, since each dose is drawn from one single-dose vial or prefilled syringe. 96372 is not a valid administration code for Lucentis on any claim, Medicare or commercial.
Payer citation language above is drawn from CareCost’s own ranibizumab policy corpus (27 payers). Check the specific payer’s language →
Wet age-related macular degeneration is a covered indication in all 27 of the ranibizumab policies CareCost has read; myopic choroidal neovascularization is covered in 26, and macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy are each covered in 25. Coverage almost always comes with a condition attached — 19 of 27 payers require another product first. Check this patient’s payer →
Sometimes, but not always the same product. 19 of 27 ranibizumab payers require another product first: bevacizumab (Avastin, off-label, repackaged) is named most often, at payers including Florida Blue, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, Capital BlueCross, Centene, Cigna, Excellus and Highmark. Other payers run a preferred-product tier naming a ranibizumab brand instead — BCBS Arkansas’s preferred list is Byooviz, Lucentis, Pavblu and Vabysmo, and “if initial request is not a preferred product, an administrative denial will be issued.” Check this patient’s payer →
21 of the 27 payers CareCost has read require an approval on file before Lucentis is covered. The packet generally needs the indication, the ICD-10 code, and documentation of which product the payer requires first — Anthem’s CC-0072 VEGF Inhibitors Step Therapy table lists Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis and Vabysmo as preferred agents effective October 30, 2023, and BCBS Arkansas states plainly that “if initial request is not a preferred product, an administrative denial will be issued.” CareCost turns the applicable payer policy into a patient-level checklist. Open patient clearance →
There is no national coverage determination for ranibizumab. Coverage runs through your MAC’s LCD for intravitreal anti-VEGF drugs, and a Medicare Advantage plan can layer its own prior-authorization rules on top of the Part B benefit. See Original Medicare details ↓
Wet AMD is a covered indication in all 27 of the ranibizumab policies CareCost has read, but coverage usually requires a step first. BCBS Michigan requires that “treatment with bevacizumab or a bevacizumab biosimilar has been ineffective, not tolerated or contraindicated”; BCBS Nebraska requires that “treatment with bevacizumab has been ineffective, not tolerated or contraindicated.” A denial usually traces back to one of those steps missing from the chart. Check this patient’s payer →
5 rules in the corpus set a reauthorization window, and most run on a 12-month cycle rather than a fixed dose count. BCBS Kansas writes that “prior authorization validity may be renewed every 12 months (365 days) thereafter, unless otherwise specified,” and Wellmark grants continued treatment on the same cycle for members who have demonstrated a positive clinical response. Myopic CNV is the exception at BCBS Kansas, where renewal runs every 3 months (90 days) instead of the annual cycle.
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · clinical prerequisite and quantity-limit criteria · reauthorization criteria. Medicare coverage from the CMS Medicare Coverage Database. Every CareCost requirement links back to its source policy.